Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry

RECOMMENDED

Pulmonary Fibrosis

Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Med

de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Guntupalli K, Bender S, Conoscenti CS, Snyder LD, IPF-PRO Registry investigators.

doi: 10.1016/j.rmed.2021.106637

RECOMMENDED

Pulmonary Fibrosis

Disease Severity and Quality of Life in Patients with Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry: Disease severity and quality of life in IPF

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Chest.

O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB, IPF-PRO™ Registry investigators

doi: 10.1016/j.chest.2019.11.042.

RECOMMENDED

Pulmonary Fibrosis

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res.

Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ

doi: 10.1186/s12931-020-1315-4.

Pulmonary Fibrosis

Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study

Lancet Respir Med.

Herazo-Maya JD, Sun J, Molyneaux PL, Li Q, Villalba JA, Tzouvelekis A, Lynn H, Juan-Guardela BM, Risquez C, Osorio JC, Yan X, Michel G, Aurelien N, Lindell KO, Klesen MJ, Moffatt MF, Cookson WO, Zhang Y, Garcia JGN, Noth I, Prasse A, Bar-Joseph Z, Gibson KF, Zhao H, Herzog EL, Rosas IO, Maher TM, Kaminski N

doi: 10.1016/

RECOMMENDED

Pulmonary Fibrosis

Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study

Eur Respir J.

Nolan CM, Maddocks M, Maher TM, Banya W, Patel S, Barker RE, Jones SE, George PM, Cullinan P, Man WD

doi: 10.1183/13993003.

RECOMMENDED

Pulmonary FibrosisPulmonary Hypertension

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry

★ 1 Recommended by Dr Martin Frey, Faculty Member

Respir Res.

Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, Maddens S, Lee YC, Kirchgaessler KU, Bartley K, Bondue B

doi: 10.1186/s12931-019-1182-z.

Interstitial Lung DiseasePulmonary Fibrosis

The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis

Respir Med.

Nathan SD, Brown AW, Mogulkoc N, Soares F, Collins AC, Cheng J, Peterson J, Cannon B, King CS, Barnett SD

doi: 10.1016/j.rmed.2020.106068.

RECOMMENDED

Pulmonary Fibrosis

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

★ 2 Recommended by Dr Martin Frey, Faculty Member

Respir Res.

Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, Kimman ML, Wijsenbeek MS

doi: 10.1186/s12931-020-01458-1.

Pulmonary Fibrosis

Impact of idiopathic pulmonary fibrosis on longitudinal healthcare utilization in a community-based cohort of patients

Chest.

Farrand E, Iribarren C, Vittinghoff E, Levine-Hall T, Ley B, Minowada G, Collard HR

doi: 10.1016/j.chest.2020.07.035.

Related content

Implementation of guideline recommendations and outcomes in patients with idiopathic pulmonary fibrosis: Data from the IPF-PRO registry

Disease Severity and Quality of Life in Patients with Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry: Disease severity and quality of life in IPF

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry

Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study

Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study

Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry

The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

Impact of idiopathic pulmonary fibrosis on longitudinal healthcare utilization in a community-based cohort of patients